CH620925A5 - - Google Patents
Download PDFInfo
- Publication number
- CH620925A5 CH620925A5 CH199377A CH199377A CH620925A5 CH 620925 A5 CH620925 A5 CH 620925A5 CH 199377 A CH199377 A CH 199377A CH 199377 A CH199377 A CH 199377A CH 620925 A5 CH620925 A5 CH 620925A5
- Authority
- CH
- Switzerland
- Prior art keywords
- amino
- formula
- piperazinyl
- dimethoxyquinazoline
- piperazine
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- -1 2,4,6,7-tetrasubstituted quinazolines Chemical class 0.000 description 21
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 13
- 208000001953 Hypotension Diseases 0.000 description 12
- 229960001289 prazosin Drugs 0.000 description 12
- 230000001077 hypotensive effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- HWIIAAVGRHKSOJ-UHFFFAOYSA-N 2-chloro-6,7-dimethoxyquinazolin-4-amine Chemical compound ClC1=NC(N)=C2C=C(OC)C(OC)=CC2=N1 HWIIAAVGRHKSOJ-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 208000021822 hypotensive Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- BAENWMYNKDCUTC-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclopentylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCC1 BAENWMYNKDCUTC-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 150000003246 quinazolines Chemical class 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 3
- CJQGSTFFFNJNMC-UHFFFAOYSA-N cyclopentyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCCC1 CJQGSTFFFNJNMC-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- GARLHAZGMDAWFE-UHFFFAOYSA-N 6,7-dimethoxy-2-piperazin-1-ylquinazoline Chemical class N1=C2C=C(OC)C(OC)=CC2=CN=C1N1CCNCC1 GARLHAZGMDAWFE-UHFFFAOYSA-N 0.000 description 2
- FYMQPWWNOCENRN-UHFFFAOYSA-N 6,7-dimethoxyquinazoline Chemical compound N1=CN=C2C=C(OC)C(OC)=CC2=C1 FYMQPWWNOCENRN-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- PBMXOVSEHBQTLI-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cycloheptylmethanone;hydrochloride Chemical compound Cl.N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCCCC1 PBMXOVSEHBQTLI-UHFFFAOYSA-N 0.000 description 2
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 2
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NEDUBQZMTKVUSV-UHFFFAOYSA-N (1-methylcyclohexyl)-piperazin-1-ylmethanone Chemical compound C1CNCCN1C(=O)C1(C)CCCCC1 NEDUBQZMTKVUSV-UHFFFAOYSA-N 0.000 description 1
- FIBLNAZZHAVWHK-UHFFFAOYSA-N (1-methylcyclopentyl)-piperazin-1-ylmethanone Chemical compound C1CNCCN1C(=O)C1(C)CCCC1 FIBLNAZZHAVWHK-UHFFFAOYSA-N 0.000 description 1
- UQCQRAUAAVOIHO-UHFFFAOYSA-N (2-chloro-6,7-dimethoxyquinazolin-4-yl)hydrazine Chemical compound ClC1=NC(NN)=C2C=C(OC)C(OC)=CC2=N1 UQCQRAUAAVOIHO-UHFFFAOYSA-N 0.000 description 1
- XDTDFGGFEUWRQQ-UHFFFAOYSA-N (2-methylcyclopentyl)-piperazin-1-ylmethanone Chemical compound CC1CCCC1C(=O)N1CCNCC1 XDTDFGGFEUWRQQ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MGHPNHISKDKRJW-UHFFFAOYSA-N 6,7-dimethoxyquinazolin-4-amine Chemical compound C1=NC(N)=C2C=C(OC)C(OC)=CC2=N1 MGHPNHISKDKRJW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QJZPGRFLOKVAOG-UHFFFAOYSA-N C1(CCCCC1)C(=O)N1CCNCC1.NC1=NC(=NC2=CC(=C(C=C12)OC)OC)N1CCN(CC1)C(=O)C1CCCCC1 Chemical compound C1(CCCCC1)C(=O)N1CCNCC1.NC1=NC(=NC2=CC(=C(C=C12)OC)OC)N1CCN(CC1)C(=O)C1CCCCC1 QJZPGRFLOKVAOG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- SCDZQNRHBYIJOT-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(1-methylcyclohexyl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1(C)CCCCC1 SCDZQNRHBYIJOT-UHFFFAOYSA-N 0.000 description 1
- WHMJPHMUKGQADL-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(1-methylcyclopentyl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1(C)CCCC1 WHMJPHMUKGQADL-UHFFFAOYSA-N 0.000 description 1
- VGCUIBNLOAKMLQ-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2-methylcyclopentyl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCC1C VGCUIBNLOAKMLQ-UHFFFAOYSA-N 0.000 description 1
- BSYQXNWTGQZJNF-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(cyclohexen-1-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CCCCC1 BSYQXNWTGQZJNF-UHFFFAOYSA-N 0.000 description 1
- ZKPIXNBQUNALFD-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(cyclopenten-1-yl)methanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CCCC1 ZKPIXNBQUNALFD-UHFFFAOYSA-N 0.000 description 1
- QVYJMOZOSBRLGX-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclobutylmethanone;hydrochloride Chemical compound Cl.N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCC1 QVYJMOZOSBRLGX-UHFFFAOYSA-N 0.000 description 1
- NGTFTEDHFMMCKI-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclohex-3-en-1-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCC=CC1 NGTFTEDHFMMCKI-UHFFFAOYSA-N 0.000 description 1
- IKQVBHDWLBYMGG-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclohexylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCCC1 IKQVBHDWLBYMGG-UHFFFAOYSA-N 0.000 description 1
- UOSFDOCRUIVVTA-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclooctylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCCCCC1 UOSFDOCRUIVVTA-UHFFFAOYSA-N 0.000 description 1
- BRECFEKDTOMWCU-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclopent-2-en-1-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCC=C1 BRECFEKDTOMWCU-UHFFFAOYSA-N 0.000 description 1
- YALCSACRZWNWRC-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclopent-3-en-1-ylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CC=CC1 YALCSACRZWNWRC-UHFFFAOYSA-N 0.000 description 1
- PQAOBJDQAFJTBT-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-cyclopropylmethanone Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CC1 PQAOBJDQAFJTBT-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- FKHMNODTEFBVPC-UHFFFAOYSA-N cyclobutyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCC1 FKHMNODTEFBVPC-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RMIBQGNVCCOQQO-UHFFFAOYSA-N cycloheptyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCCCCC1 RMIBQGNVCCOQQO-UHFFFAOYSA-N 0.000 description 1
- WKLPKXATXOPSKH-UHFFFAOYSA-N cyclohex-3-en-1-yl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCC=CC1 WKLPKXATXOPSKH-UHFFFAOYSA-N 0.000 description 1
- YNEOVTHPUUPULA-UHFFFAOYSA-N cyclohexen-1-yl(piperazin-1-yl)methanone Chemical compound C=1CCCCC=1C(=O)N1CCNCC1 YNEOVTHPUUPULA-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- YXBPNQNZBVOERG-UHFFFAOYSA-N cyclooctyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCCCCCC1 YXBPNQNZBVOERG-UHFFFAOYSA-N 0.000 description 1
- FUEQFFCZAGYXHW-UHFFFAOYSA-N cyclopent-2-en-1-yl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CCC=C1 FUEQFFCZAGYXHW-UHFFFAOYSA-N 0.000 description 1
- BQKUNHBVCSMMBB-UHFFFAOYSA-N cyclopent-3-en-1-yl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CC=CC1 BQKUNHBVCSMMBB-UHFFFAOYSA-N 0.000 description 1
- OQCVPEIHYUPZCC-UHFFFAOYSA-N cyclopenten-1-yl(piperazin-1-yl)methanone Chemical compound C=1CCCC=1C(=O)N1CCNCC1 OQCVPEIHYUPZCC-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VMRPBDVKSOCEOM-UHFFFAOYSA-N cyclopentyl-[4-(4-hydrazinyl-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]methanone;hydrochloride Chemical compound Cl.N=1C(NN)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCC1 VMRPBDVKSOCEOM-UHFFFAOYSA-N 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- KIALFUYSJAAJSU-UHFFFAOYSA-N cyclopropyl(piperazin-1-yl)methanone Chemical compound C1CNCCN1C(=O)C1CC1 KIALFUYSJAAJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/659,059 US4060615A (en) | 1976-02-18 | 1976-02-18 | 2-Piperazinyl-6,7-dimethoxyquinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH620925A5 true CH620925A5 (de) | 1980-12-31 |
Family
ID=24643862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH199377A CH620925A5 (de) | 1976-02-18 | 1977-02-17 | |
| CH88580A CH623051A5 (de) | 1976-02-18 | 1980-02-04 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH88580A CH623051A5 (de) | 1976-02-18 | 1980-02-04 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4060615A (de) |
| JP (1) | JPS52100479A (de) |
| AU (1) | AU505080B2 (de) |
| BE (1) | BE851447A (de) |
| CA (1) | CA1090803A (de) |
| CH (2) | CH620925A5 (de) |
| CY (1) | CY1155A (de) |
| DE (1) | DE2707068A1 (de) |
| DK (1) | DK144010C (de) |
| FI (1) | FI64586C (de) |
| FR (1) | FR2341576A1 (de) |
| GB (1) | GB1545697A (de) |
| HK (1) | HK32682A (de) |
| IE (1) | IE44613B1 (de) |
| KE (1) | KE3221A (de) |
| LU (1) | LU76779A1 (de) |
| MY (1) | MY8300172A (de) |
| NL (1) | NL7701584A (de) |
| SE (1) | SE431753B (de) |
| SG (1) | SG30882G (de) |
| YU (4) | YU42577A (de) |
| ZA (1) | ZA77587B (de) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
| JPS6016948B2 (ja) * | 1978-03-29 | 1985-04-30 | 住友化学工業株式会社 | 新規なキナゾリン誘導体及びその製造法 |
| US4287341A (en) * | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
| EP0022481A1 (de) * | 1979-06-21 | 1981-01-21 | Mitsubishi Yuka Pharmaceutical Co., Ltd. | 5,6-Alkylenpyrimidin-Derivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen |
| GB2068961B (en) * | 1980-02-13 | 1983-11-30 | Sankyo Co | Quinazoline derivatives |
| US4377581A (en) * | 1980-03-03 | 1983-03-22 | Pfizer Inc. | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines |
| US4351940A (en) * | 1980-03-03 | 1982-09-28 | Pfizer Inc. | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines |
| US4367335A (en) * | 1981-08-03 | 1983-01-04 | Mead Johnson & Company | Thiazolidinylalkylene piperazine derivatives |
| DE3304292A1 (de) * | 1982-10-11 | 1984-04-12 | Brown, Boveri & Cie Ag, 6800 Mannheim | Verfahren und vorrichtung zum ausregeln von netzfrequenzeinbruechen bei einem gleitdruckbetriebenen dampfkraftwerkblock |
| DE3346675A1 (de) * | 1983-12-23 | 1985-07-04 | Beiersdorf Ag, 2000 Hamburg | Substituierte 1-(4-amino-6,7-dialkoxy-chinazolinyl)-4- cyclohexenyl-derivate des piperazins und homopiperazins, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen und zwischenprodukte |
| AT384218B (de) * | 1985-12-04 | 1987-10-12 | Gerot Pharmazeutika | Verfahren zur herstellung von neuen chinazolin-derivaten |
| JP2657760B2 (ja) * | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | ４−アミノキナゾリン誘導体およびそれを含有する医薬品 |
| CA2077252C (en) * | 1992-08-31 | 2001-04-10 | Khashayar Karimian | Methods of making ureas and guanidines, and intermediates therefor |
| US20060222647A1 (en) * | 1993-05-27 | 2006-10-05 | Beavo Joseph A | Methods and compositions for modulating the activity of PDE5 |
| US5696159A (en) * | 1994-08-03 | 1997-12-09 | Cell Pathways, Inc. | Lactone compounds for treating patients with precancerous lesions |
| US5776962A (en) * | 1994-08-03 | 1998-07-07 | Cell Pathways, Inc. | Lactone compounds for treating patient with precancerous lesions |
| US5869486A (en) * | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| US6046216A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives |
| US6232312B1 (en) | 1995-06-07 | 2001-05-15 | Cell Pathways, Inc. | Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides |
| US6262059B1 (en) | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
| US6200980B1 (en) | 1995-06-07 | 2001-03-13 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl purinone derivatives |
| US6060477A (en) * | 1995-06-07 | 2000-05-09 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| US5874440A (en) * | 1995-06-07 | 1999-02-23 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives |
| US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
| GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
| CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| UA46166C2 (uk) * | 1997-11-12 | 2002-05-15 | Баєр Акцієнгезельшафт | 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі |
| US5852035A (en) * | 1997-12-12 | 1998-12-22 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines |
| US6410584B1 (en) * | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
| US6046199A (en) * | 1998-01-14 | 2000-04-04 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives |
| US5942520A (en) * | 1998-01-27 | 1999-08-24 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines |
| US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
| US6180629B1 (en) | 1998-08-14 | 2001-01-30 | Cell Pathways, Inc. | [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia |
| US6124303A (en) * | 1998-09-11 | 2000-09-26 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones |
| US6268372B1 (en) | 1998-09-11 | 2001-07-31 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones |
| US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
| US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
| US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
| US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
| US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
| US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
| US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
| US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
| US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
| US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
| US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
| US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
| EP1364950A4 (de) * | 2001-02-26 | 2005-03-09 | Tanabe Seiyaku Co | Pyridopyrimidin- und naphthyridinderivate |
| CA2449163C (en) * | 2001-05-09 | 2010-07-13 | Bayer Healthcare Ag | New use of 2-phenyl-substituted imidazotriazinones |
| EP1312363A1 (de) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Behandlungsverfahren und kits bestehend aus Wachstumshormonsekretionsförderern |
| US7342884B2 (en) * | 2002-03-13 | 2008-03-11 | Harmonic, Inc. | Method and apparatus for one directional communications in bidirectional communications channel |
| US7893101B2 (en) * | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US7208516B2 (en) * | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7276529B2 (en) * | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| MXPA04009997A (es) * | 2002-04-12 | 2004-12-13 | Celgene Corp | Modulacion de la diferenciacion de celulas madre y progenitoras, ensayos y usos de las mismas. |
| WO2003086373A1 (en) * | 2002-04-12 | 2003-10-23 | Celgene Corporation | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
| DE10232113A1 (de) * | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
| NZ547327A (en) | 2003-11-21 | 2009-08-28 | Array Biopharma Inc | AKT protein kinase inhibitors |
| DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
| DE102005009241A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit kontrollierter Bioverfügbarkeit |
| DE102005009240A1 (de) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften |
| AU2006299232A1 (en) * | 2005-09-29 | 2007-04-12 | Bayer Schering Pharma Aktiengesellschaft | PDE inhibitors and combinations thereof for the treatment of urological disorders |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| CA2656566C (en) | 2006-07-06 | 2014-06-17 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2008006039A1 (en) | 2006-07-06 | 2008-01-10 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| NZ573979A (en) * | 2006-07-06 | 2012-02-24 | Array Biopharma Inc | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| WO2008151734A1 (en) * | 2007-06-13 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of hearing impairment |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| MX2009014013A (es) * | 2007-07-05 | 2010-01-28 | Array Biopharma Inc | Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt. |
| BRPI0813999A2 (pt) | 2007-07-05 | 2019-10-01 | Array Biopharma Inc | ciclopentanos de pirimidil como inibidores de akt proteína cinase |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| NZ586720A (en) * | 2008-01-09 | 2012-11-30 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| EP2247578B1 (de) * | 2008-01-09 | 2013-05-22 | Array Biopharma, Inc. | Hydroxylierte pyrimidylcyclopentane als akt-proteinkinaseinhibitoren |
| WO2009120296A1 (en) * | 2008-03-24 | 2009-10-01 | Celgene Corporation | Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
| SG194045A1 (en) | 2011-04-01 | 2013-11-29 | Genentech Inc | Combinations of akt inhibitor compounds and abiraterone, and methods of use |
| KR20140022053A (ko) | 2011-04-01 | 2014-02-21 | 제넨테크, 인크. | Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법 |
| JP6687550B2 (ja) | 2014-06-23 | 2020-04-22 | セルジーン コーポレイション | 肝疾患又は肝機能異常を治療するためのアプレミラスト |
| US11944624B2 (en) * | 2017-07-06 | 2024-04-02 | Case Western Reserve University | Peptide and small molecule agonists of EphA and their uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3511836A (en) * | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| US3669968A (en) * | 1970-05-21 | 1972-06-13 | Pfizer | Trialkoxy quinazolines |
| JPS536156B2 (de) * | 1972-10-30 | 1978-03-04 | ||
| US3935213A (en) * | 1973-12-05 | 1976-01-27 | Pfizer Inc. | Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives |
-
1976
- 1976-02-18 US US05/659,059 patent/US4060615A/en not_active Expired - Lifetime
-
1977
- 1977-01-20 CA CA270,098A patent/CA1090803A/en not_active Expired
- 1977-02-02 ZA ZA770587A patent/ZA77587B/xx unknown
- 1977-02-03 AU AU21897/77A patent/AU505080B2/en not_active Expired
- 1977-02-15 NL NL7701584A patent/NL7701584A/xx not_active Application Discontinuation
- 1977-02-15 FI FI770486A patent/FI64586C/fi not_active IP Right Cessation
- 1977-02-15 BE BE174951A patent/BE851447A/xx not_active IP Right Cessation
- 1977-02-15 DK DK65077A patent/DK144010C/da not_active IP Right Cessation
- 1977-02-16 SE SE7701731A patent/SE431753B/xx unknown
- 1977-02-16 FR FR7704348A patent/FR2341576A1/fr active Granted
- 1977-02-16 JP JP1511077A patent/JPS52100479A/ja active Pending
- 1977-02-16 LU LU76779A patent/LU76779A1/xx unknown
- 1977-02-17 CH CH199377A patent/CH620925A5/fr not_active IP Right Cessation
- 1977-02-17 YU YU00425/77A patent/YU42577A/xx unknown
- 1977-02-17 GB GB6703/77A patent/GB1545697A/en not_active Expired
- 1977-02-17 IE IE337/77A patent/IE44613B1/en unknown
- 1977-02-17 CY CY1155A patent/CY1155A/xx unknown
- 1977-02-18 DE DE19772707068 patent/DE2707068A1/de not_active Withdrawn
-
1980
- 1980-02-04 CH CH88580A patent/CH623051A5/fr not_active IP Right Cessation
-
1982
- 1982-07-06 SG SG308/82A patent/SG30882G/en unknown
- 1982-07-07 KE KE3221A patent/KE3221A/xx unknown
- 1982-07-15 HK HK326/82A patent/HK32682A/xx unknown
- 1982-07-28 YU YU1653/82A patent/YU40622B/xx unknown
- 1982-07-28 YU YU01652/82A patent/YU165282A/xx unknown
- 1982-07-28 YU YU01654/82A patent/YU165482A/xx unknown
-
1983
- 1983-12-30 MY MY172/83A patent/MY8300172A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI770486A (de) | 1977-08-19 |
| IE44613B1 (en) | 1982-01-27 |
| IE44613L (en) | 1977-08-18 |
| FI64586B (fi) | 1983-08-31 |
| ZA77587B (en) | 1977-12-28 |
| CY1155A (en) | 1983-01-28 |
| CA1090803A (en) | 1980-12-02 |
| YU42577A (en) | 1982-10-31 |
| FR2341576A1 (fr) | 1977-09-16 |
| MY8300172A (en) | 1983-12-31 |
| JPS52100479A (en) | 1977-08-23 |
| AU505080B2 (en) | 1979-11-08 |
| FR2341576B1 (de) | 1979-01-19 |
| US4060615A (en) | 1977-11-29 |
| SG30882G (en) | 1983-07-08 |
| YU165282A (en) | 1982-10-31 |
| SE431753B (sv) | 1984-02-27 |
| YU40622B (en) | 1986-02-28 |
| BE851447A (fr) | 1977-08-16 |
| HK32682A (en) | 1982-07-23 |
| LU76779A1 (de) | 1977-08-19 |
| CH623051A5 (de) | 1981-05-15 |
| YU165382A (en) | 1982-10-31 |
| DK144010C (da) | 1982-04-26 |
| AU2189777A (en) | 1978-08-10 |
| GB1545697A (en) | 1979-05-10 |
| FI64586C (fi) | 1983-12-12 |
| SE7701731L (sv) | 1977-08-19 |
| DK65077A (da) | 1977-08-19 |
| YU165482A (en) | 1982-10-31 |
| DE2707068A1 (de) | 1977-09-01 |
| NL7701584A (nl) | 1977-08-22 |
| KE3221A (en) | 1982-08-13 |
| DK144010B (da) | 1981-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH620925A5 (de) | ||
| EP3626699A1 (de) | Ssao-inhibitor | |
| EP1250328B1 (de) | Dihydro-1,3,5-triazin-diamin-derivate und ihre therapeutische verwendung | |
| EP0506532B1 (de) | Indolderivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| CH639653A5 (fr) | Aminothiazoles et composition pharmaceutique les contenant. | |
| DE69108913T2 (de) | 4-alkylimidazolderivate. | |
| EP0110781B1 (de) | Substituierte (Amino-2-ethyl)-6-Benzoxazolinone, ihre Herstellung und pharmazeutische Zusammenstellung die sie enthält | |
| LU85442A1 (fr) | Agents antidepression a base de 1,2,4-triazol-3-one | |
| EP0350448A1 (de) | Biarylverbindungen | |
| FI80262C (fi) | Foerfarande foer framstaellning av saosom antiiskemiska och antihypertensiva medel anvaendbara 1,4-dihydropyridinderivat. | |
| EP0446141B1 (de) | Imidazo[1,2-c]chinazolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| EP0527081B1 (de) | Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde | |
| US20090325979A1 (en) | Novel imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | |
| FR2533563A1 (fr) | Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant | |
| LU86421A1 (fr) | Derives de piperazine 1,4-disubstitues,composition pharmaceutique les contenant;leur procede d'obtention | |
| US5214053A (en) | Thiourea derivatives and antimicrobial agent and antiulcer agent containing the same | |
| EP1659112B1 (de) | Arylpiperazinderivate als selektive Liganden für den Dopamin D3 Rezeptor | |
| FR2893616A1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant | |
| EP1023898A1 (de) | Cyano-indolen als Serotoninwiederaufnahme Inhibitoren und als 5-HT2c Rezeptor Liganden | |
| BE898151A (fr) | Nouveaux dérivés de la quinazoline, leur préparation et leur utilisation comme médicaments. | |
| FR2510571A1 (fr) | Spirothiazolidinedione, son procede de production et preparation pharmaceutique la contenant | |
| JPS62111970A (ja) | 置換された３−（４−フエニル−１−ピペラジニル）アルキルキナゾリン−２，４−（１ｈ，３ｈ）ジオン類 | |
| EP0502110B1 (de) | 4-(hetero)arylmethyloxy-phenyl-diazolderivate, verfahren zu deren herstellung und ihre therapeutische verwendung | |
| JP7506415B2 (ja) | Ｖａｎｉｎ－１阻害剤 | |
| FR2765223A1 (fr) | Nouveaux derives tricycliques du benzimidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |